Molina Healthcare (MOH) PT Lowered to $124 by Goldman Sachs Following Q4 Earnings Miss

Group 1 - Molina Healthcare Inc. (NYSE:MOH) is considered one of the most undervalued mid-cap stocks currently available for investment [1] - Goldman Sachs lowered its price target for Molina Healthcare to $124 from $167 while maintaining a Neutral rating after the company's Q4 2025 earnings miss [1][4] - UBS analyst AJ Rice also reduced the price target for Molina Healthcare to $145 from $170, citing challenges in the Medicaid and exchanges backdrop while keeping a Neutral rating [3] Group 2 - The return profiles for strong operators in low-margin, government-priced cyclical businesses, such as managed care organizations, can diminish rapidly during economic downturns [2] - Goldman Sachs anticipates that challenges in the managed care sector will persist due to its sensitivity to the current cyclical environment [2]